现实世界的经验量化了对JAK抑制剂治疗脱发症患者的治疗机会:以患者为中心的调查研究
Ambika Nohria1, Ya-Han Crystal Zhang1, Deesha Desai1,2
1The Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York, New York.
International journal of women's dermatology
|April 12, 2024
概括
雅努斯酶抑制剂 (JAKi) 治疗大发性脱毛症 (AA) 是革命性的,但面临着进入障碍. 许多患者经历了保险问题,高成本和延误,突出了改善AA治疗准入和公平的需要.
科学领域:
- 皮肤病学 皮肤病学
- 药物经济学 药物经济学
- 健康 公平 卫生 公平
背景情况:
- 雅努斯酶抑制剂 (JAKi) 疗法已经改变了白发性 (AA) 治疗.
- 然而,保险覆盖和高的自费费用限制了患者获得JAKi治疗的机会.
研究的目的:
- 评估真实世界的患者经验,以获得AA的JAKi治疗.
- 识别JAKi治疗获得的障碍和差异.
主要方法:
- 一项以患者为中心的在线调查通过国家脱发区基金会列表服务分发.
- 从600个完成的调查中收集了数据.
主要成果:
- 74.2%的患者没有足够的保险覆盖JAKi治疗.
- 52.9%的患者因保险而出现治疗延迟,而35%的患者因担心成本而避免接受JAKi治疗.
- 观察到JAKi考虑和利用的种族差异,影响不同患者群体的财务障碍.
结论:
- 严重的财务和保险相关障碍阻碍了AA患者获得JAKi治疗的机会.
- 医疗保健中现有的种族不平等可能会因这些接入挑战而恶化.
- 进一步宣传至关重要,以加强平等获得基本的AA治疗.
相关概念视频
The JAK-STAT Signaling Pathway
10.3K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
10.3K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
631
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
631
Bioavailability Study Design: Healthy Subjects Versus Patients
252
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
252
Cancer Survival Analysis
870
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
870


